BioSyent Pharma Inc.

16 articles about BioSyent Pharma Inc.

• BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer

  7/6/2023

  BioSyent Pharma Inc., a subsidiary of BioSyent Inc., is attending the American Head and Neck Society 11th International Conference on Head and Neck Cancer in Montreal, Quebec on July 8-12, 2023 to promote Gelclair®, its new oncology supportive care product.

• BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product

  12/14/2022

  BioSyent Inc. is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive Distribution Agreement with a European partner for a product that is used in oncology supportive care.

• Photocure launches Cysview Commercial Operations in Canada

  1/3/2022

  Press release - Oslo, Norway, 3 January 2022: Photocure ASA announces the start of its Cysview® sales, marketing and distribution operations in the Canadian market.

• BioSyent Signs Exclusive Technology Agreement

  7/13/2021

  BioSyent Inc. is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron deficiencies in Canada and BioSyent’s international markets.

• BioSyent Releases Results for Third Quarter and First Nine Months of 2017

  11/15/2017

  Third quarter (Q3) 2017 Net Revenues of $5,403,600 increased by 13% versus Q3 2016.

• BioSyent Pharma Inc. Receives Health Canada Approval for New In-Licensed Topical Anesthetic

  7/29/2011

• BioSyent Pharma Inc. Returns Virsani(TM) Distribution Rights To Notlers

  7/14/2010

• BioSyent Pharma Inc. Signs License and Distribution Agreement With Notlers

  1/22/2010

• BioSyent Pharma Inc. Signs Exclusive Product Development, Supply and Distribution Agreement

  9/1/2009

• BioSyent Pharma Inc. Signs License, Supply and Distribution Agreement

  7/15/2009

• BioSyent Pharma Inc. Establishes Hospital Products Division-Secures First Supply Contract and Orders for New Product

  5/14/2008

• BioSyent Pharma Inc. Launches Feramax'TM': A Unique Oral Hematinic

  9/25/2006

• Vanderbilt-Ingram Cancer Center Signs On With Open Biosystems' Open Access(TM) Program For Breast Cancer Research; Leading Cancer Centers Continue To Recognize The Value Of shRNAmir And cDNA Technology

  9/11/2006

• BioSyent Inc. Updates Sales Progress: Product Sales Year-to-Date Increase 84%

  9/8/2006

• BioSyent Inc. Signs Product Sourcing And Distribution Agreement: Foundation For Up To Five New Products

  8/9/2006

• BioSyent Pharma Inc. Secures Health Canada Site Licence

  6/20/2006